Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study - PubMed (original) (raw)
Multicenter Study
Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study
Lauren E Mokry et al. PLoS Med. 2015.
Erratum in
- Correction: Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study.
Mokry LE, Ross S, Ahmad OS, Forgetta V, Smith GD, Goltzman D, Leong A, Greenwood CM, Thanassoulis G, Richards JB. Mokry LE, et al. PLoS Med. 2016 Mar 2;13(3):e1001981. doi: 10.1371/journal.pmed.1001981. eCollection 2016 Mar. PLoS Med. 2016. PMID: 26963823 Free PMC article. No abstract available.
Abstract
Background: Observational studies have demonstrated an association between decreased vitamin D level and risk of multiple sclerosis (MS); however, it remains unclear whether this relationship is causal. We undertook a Mendelian randomization (MR) study to evaluate whether genetically lowered vitamin D level influences the risk of MS.
Methods and findings: We identified single nucleotide polymorphisms (SNPs) associated with 25-hydroxyvitamin D (25OHD) level from SUNLIGHT, the largest (n = 33,996) genome-wide association study to date for vitamin D. Four SNPs were genome-wide significant for 25OHD level (p-values ranging from 6 × 10-10 to 2 × 10-109), and all four SNPs lay in, or near, genes strongly implicated in separate mechanisms influencing 25OHD. We then ascertained their effect on 25OHD level in 2,347 participants from a population-based cohort, the Canadian Multicentre Osteoporosis Study, and tested the extent to which the 25OHD-decreasing alleles explained variation in 25OHD level. We found that the count of 25OHD-decreasing alleles across these four SNPs was strongly associated with lower 25OHD level (n = 2,347, F-test statistic = 49.7, p = 2.4 × 10-12). Next, we conducted an MR study to describe the effect of genetically lowered 25OHD on the odds of MS in the International Multiple Sclerosis Genetics Consortium study, the largest genetic association study to date for MS (including up to 14,498 cases and 24,091 healthy controls). Alleles were weighted by their relative effect on 25OHD level, and sensitivity analyses were performed to test MR assumptions. MR analyses found that each genetically determined one-standard-deviation decrease in log-transformed 25OHD level conferred a 2.0-fold increase in the odds of MS (95% CI: 1.7-2.5; p = 7.7 × 10-12; I2 = 63%, 95% CI: 0%-88%). This result persisted in sensitivity analyses excluding SNPs possibly influenced by population stratification or pleiotropy (odds ratio [OR] = 1.7, 95% CI: 1.3-2.2; p = 2.3 × 10-5; I2 = 47%, 95% CI: 0%-85%) and including only SNPs involved in 25OHD synthesis or metabolism (ORsynthesis = 2.1, 95% CI: 1.6-2.6, p = 1 × 10-9; ORmetabolism = 1.9, 95% CI: 1.3-2.7, p = 0.002). While these sensitivity analyses decreased the possibility that pleiotropy may have biased the results, residual pleiotropy is difficult to exclude entirely.
Conclusions: A genetically lowered 25OHD level is strongly associated with increased susceptibility to MS. Whether vitamin D sufficiency can delay, or prevent, MS onset merits further investigation in long-term randomized controlled trials.
Conflict of interest statement
GT has accepted speaker's fees and consultancy fees from Servier Canada relating to the treatment of hypertension and has participated on an Advisory Board for ISIS Pharmaceuticals for the treatment of dyslipidemia. GT also receives research grants from the Canadian Institute of Health Research and the Heart and Stroke Foundation of Canada. GDS is a member of the Editorial Board of PLOS Medicine. None of these relationships relate to the content/topic of the manuscript under review at PLOS Medicine.
Figures
Fig 1. Schematic representation of Mendelian randomization analysis.
The leftmost box lists SNPs that were genome-wide significant for 25OHD level in SUNLIGHT (n = 33,996). The blue arrow represents the effect of SNPs on multiply adjusted natural-log-transformed 25OHD level using data from CaMos (n = 2,347). The green arrow represents the causal association of decreased 25OHD level with the risk of MS using data from the largest genetic association study to date for MS (the IMSGC Immunochip study, up to 14,498 cases and 24,091 healthy controls).
Fig 2. Vitamin D pathway.
In blue are the genes containing, or in proximity to, SNPs that were genome-wide significant for 25OHD level in SUNLIGHT (n = 33,996). The _p_-values for the association with 25OHD level were 1.9 × 10−109 for GC, 2.1 × 10−27 for DHCR7, 3.3 × 10−20 for CYP2R1, and 6.0 × 10−10 for CYP24A1. Note that each gene plays an independent role in modulating the level of 25OHD. Kidney and liver images credit:
.
Fig 3. 25OHD level by number of 25OHD-decreasing alleles in the CaMos cohort.
Here we show the box-plot of natural-log-transformed 25OHD by the count of 25OHD-decreasing alleles in the CaMos population. A count of zero represents individuals with no 25OHD-decreasing alleles (or homozygous at each loci for the 25OHD-increasing allele), and a count of six represents an individual with six 25OHD-decreasing alleles. No individuals with a count of seven or more 25OHD-decreasing alleles were observed in this cohort. The center line and error bars represent the mean level of natural-log-transformed 25OHD and its 95% CI for each respective allele count. Note a negative trend between allele count and mean natural-log-transformed 25OHD.
Fig 4. Mendelian randomization estimate of the association of 25OHD level with risk of multiple sclerosis.
Estimates obtained using a fixed-effects model.
Fig 5. Mendelian randomization estimate of the association of 25OHD level with risk of multiple sclerosis excluding the DHCR7 locus.
Estimates obtained using a fixed-effects model.
Similar articles
- Mendelian Randomization Studies Do Not Support a Role for Vitamin D in Coronary Artery Disease.
Manousaki D, Mokry LE, Ross S, Goltzman D, Richards JB. Manousaki D, et al. Circ Cardiovasc Genet. 2016 Aug;9(4):349-56. doi: 10.1161/CIRCGENETICS.116.001396. Epub 2016 Jul 14. Circ Cardiovasc Genet. 2016. PMID: 27418593 - Vitamin D levels and risk of type 1 diabetes: A Mendelian randomization study.
Manousaki D, Harroud A, Mitchell RE, Ross S, Forgetta V, Timpson NJ, Smith GD, Polychronakos C, Richards JB. Manousaki D, et al. PLoS Med. 2021 Feb 25;18(2):e1003536. doi: 10.1371/journal.pmed.1003536. eCollection 2021 Feb. PLoS Med. 2021. PMID: 33630834 Free PMC article. Clinical Trial. - Vitamin D levels and susceptibility to asthma, elevated immunoglobulin E levels, and atopic dermatitis: A Mendelian randomization study.
Manousaki D, Paternoster L, Standl M, Moffatt MF, Farrall M, Bouzigon E, Strachan DP, Demenais F, Lathrop M, Cookson WOCM, Richards JB. Manousaki D, et al. PLoS Med. 2017 May 9;14(5):e1002294. doi: 10.1371/journal.pmed.1002294. eCollection 2017 May. PLoS Med. 2017. PMID: 28486474 Free PMC article. - Phenome-wide Mendelian randomization study evaluating the association of circulating vitamin D with complex diseases.
Xu JJ, Zhang XB, Tong WT, Ying T, Liu KQ. Xu JJ, et al. Front Nutr. 2023 Mar 29;10:1108477. doi: 10.3389/fnut.2023.1108477. eCollection 2023. Front Nutr. 2023. PMID: 37063319 Free PMC article. Review. - Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies.
Vandebergh M, Degryse N, Dubois B, Goris A. Vandebergh M, et al. J Neurol. 2022 Aug;269(8):4565-4574. doi: 10.1007/s00415-022-11072-4. Epub 2022 Apr 2. J Neurol. 2022. PMID: 35366084 Review.
Cited by
- Selecting Invalid Instruments to Improve Mendelian Randomization with Two-Sample Summary Data.
Patel A, DiTraglia FJ, Zuber V, Burgess S. Patel A, et al. Ann Appl Stat. 2024 Apr 5;18(2):23-aoas1856. doi: 10.1214/23-AOAS1856. eCollection 2024 Jun 1. Ann Appl Stat. 2024. PMID: 38737575 Free PMC article. - Phenomewide Association Study of Health Outcomes Associated With the Genetic Correlates of 25 Hydroxyvitamin D Concentration and Vitamin D Binding Protein Concentration.
Kresge HA, Blostein F, Goleva S, Albiñana C, Revez JA, Wray NR, Vilhjálmsson BJ, Zhu Z, McGrath JJ, Davis LK. Kresge HA, et al. Twin Res Hum Genet. 2024 Apr;27(2):69-79. doi: 10.1017/thg.2024.19. Epub 2024 Apr 22. Twin Res Hum Genet. 2024. PMID: 38644690 Free PMC article. - Controlling for polygenic genetic confounding in epidemiologic association studies.
Zhao Z, Yang X, Miao J, Dorn S, Barcellos SH, Fletcher JM, Lu Q. Zhao Z, et al. bioRxiv [Preprint]. 2024 Feb 14:2024.02.12.579913. doi: 10.1101/2024.02.12.579913. bioRxiv. 2024. PMID: 38405812 Free PMC article. Preprint. - Incorporating biological and clinical insights into variant choice for Mendelian randomisation: examples and principles.
Burgess S, Cronjé HT. Burgess S, et al. eGastroenterology. 2024 Jan;2(1):e100042. doi: 10.1136/egastro-2023-100042. Epub 2024 Jan 22. eGastroenterology. 2024. PMID: 38362310 Free PMC article. - Evidence supports a causal association between allele-specific vitamin D receptor binding and multiple sclerosis among Europeans.
Adams C, Manouchehrinia A, Quach HL, Quach DL, Olsson T, Kockum I, Schaefer C, Ponting CP, Alfredsson L, Barcellos LF. Adams C, et al. Proc Natl Acad Sci U S A. 2024 Feb 20;121(8):e2302259121. doi: 10.1073/pnas.2302259121. Epub 2024 Feb 12. Proc Natl Acad Sci U S A. 2024. PMID: 38346204 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical